

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT – TERMINATION OF FRAMEWORK AGREEMENT IN RESPECT OF FORMATION OF JOINT VENTURE

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”).

Reference is made to the announcement of the Company dated 29 December 2016 (the “**Announcement**”). Save as otherwise provided in this announcement, capitalized terms used herein shall have the same meanings as used in the Announcement.

THE BACKGROUND

As disclosed in the Announcement, the Company and (a) China Resources Pharmaceutical Group Limited and (b) China Resources Pharmaceutical Industry Development (Beijing) Co., Ltd. (collectively the “**China Resources Parties**”) (both of which China Resources Group is the controlling shareholder) have entered into the Framework Agreement to elaborate certain details of the Original Framework Agreement in relation to the Project.

TERMINATION OF AGREEMENT

Upon internal review by the Company and the China Resources Parties, it is expected that the parties could not enter into a formal joint venture agreement in respect of the Project before 30 June 2017. Therefore, the board of directors of the Company (the “**Board**”) announces that on 16 March 2017 (after trading hour), after negotiation on friendly basis, the Company and the China Resources Parties have entered into a termination agreement (the “**Termination Agreement**”) to terminate the Framework Agreement (the “**Termination**”).

Pursuant to the Termination Agreement, the Company and the China Resources Parties have agreed, among others, to terminate further negotiation on the Project according to the Framework Agreement with effect from the effective date of the Termination Agreement, and to bear all costs and expenses incurred for the Project by themselves respectively.

The Board considers that the Termination will not have any material adverse effect on the operation and financial position of the Company and its subsidiaries.

By Order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 16 March 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*